Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction

American Journal of Epidemiology

Volumn 163, Issue 11, 2006, Pages 1035-1041

  Grosso, Laura M ^a   Triche, Elizabeth W ^a   Belanger, Kathleen ^a   Benowitz, Neal L ^b   Holford, Theodore R ^a   Bracken, Michael B ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood; Caffeine; Cytochrome P 450 enzyme system; Fetal blood; Fetal development; Pregnancy; Reproduction; Umbilical cord

Indexed keywords

CAFFEINE; CAFFEINE DERIVATIVE; CYTOCHROME P450 1A2; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

CYTOCHROME; GROWTH FAULT; HOSPITAL SECTOR; MATERNAL HEALTH; METABOLISM; METABOLITE; PREGNANCY; REPRODUCTIVE BEHAVIOR; RESEARCH WORK;

ARTICLE; BLOOD LEVEL; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; FETUS GROWTH; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; METABOLITE; OUTCOME ASSESSMENT; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL EXPOSURE; PRENATAL PERIOD; RISK REDUCTION; SELF REPORT; STATISTICAL MODEL; UMBILICAL CORD BLOOD; UNITED STATES;

ADULT; BIOLOGICAL MARKERS; CAFFEINE; CHI-SQUARE DISTRIBUTION; CONNECTICUT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FETAL BLOOD; FETAL GROWTH RETARDATION; HUMANS; MASSACHUSETTS; MATERNAL-FETAL EXCHANGE; MOTHERS; PREGNANCY; PREGNANCY OUTCOME; RISK FACTORS; STATISTICS, NONPARAMETRIC; THEOBROMINE; THEOPHYLLINE;

EID: 33745594038     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj125     Document Type: Article

References (30)

1. Bracken MB, Triche EW, Grosso LM, et al. Heterogeneity in assessing self-reports of caffeine exposure: implications for studies of health effects. Epidemiology 2002;13:165-71.
2. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYPIA2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
3. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125:803-8.
4. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17x/137x) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001;11:429-35.
5. Grosso LM, Bracken MB. Caffeine metabolism, genetics and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol 2005;15:457-63.
6. Arnaud MJ. Metabolism of caffeine and other components of coffee. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, 1993:43-95.
7. Weathersbee PS, Lodge JR. Caffeine: its direct and indirect influence on reproduction. J Reprod Med 1977;19:55-63.
8. Parsons WD, Aranda J, Neims AH. Elimination of transplacentally acquired caffeine in fullterm neonates. (Abstract). Pediatr Res 1976;10:33.
9. Daly JW. Mechanism of action of caffeine. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, 1993:97-149.
10. Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med 1990;41:277-8.
11. Aldridge A, Bailey J, Neims AH. The disposition of caffeine during and after pregnancy. Semin Perinatol 1981;5:310-14.
12. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978;24:734-9.
13. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
14. Cook DG, Peacock JL, Feyerabend C, et al. Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: prospective population based study. BMJ 1996;313:1358-62.
15. Arnaud MJ, Murray C, Youssif A, et al. Caffeine consumption and metabolism in pregnant women during the third-trimester pregnancy. Montpellier: International Scientific Colloquium on Coffee/International Scientific Association of Coffee, Montpellier. Vol II. Paris, France: Association Scientifique Internationale du Café (ASIC), 1993:433-41.
16. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 2001;70:121-5.
17. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6, and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-9.
18. Santos IS, Victora CG, Huttly S, et al. Caffeine intake and low birth weight: a population-based case-control study. Am J Epidemiol 1998;147:620-7.
19. Centers for Disease Control and Prevention, National Center for Health Statistics. 1999 natality detail file, issued June 2001. (NCHS CD-ROM series 21, no. 12H, ASCII version).
20. Fuhr U, Rost KL, Engelhardt R, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2, and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996;6:159-76.
21. SAS Institute, Inc. Statistical analysis system. Cary, NC: SAS Institute, Inc, 2001.
22. Klebanoff MA, Levine RJ, Clemens JD, et al. Maternal serum caffeine metabolites and small-for-gestational-age birth. Am J Epidemiol 2002;155:32-7.
23. Klebanoff M, Levine R, DerSimonian R, et al. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 1999;341:1639-44.
24. Soyka LS, Neese AL, Main D, et al. Studies of caffeine and theophylline in the neonate. Semin Perinatol 1981;5:332-6.
25. Spigset O, Hagg S, Soderstrom E, et al. The paraxanthine:-caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 1999;9:409-12.
26. Doude van Troostwijk LJ, Koopmans RP, Guchelaar HJ. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Fundam Clin Pharmacol 2003;17:355-62.
27. Lambert GH, Schoeller DA, Humphrey HE, et al. The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. Environ Health Perspect 1990;89:175-81.
28. Halperin W, Kalow W, Sweeney MH, et al. Induction of P-450 in workers exposed to dioxin. Occup Environ Med 1995;52:86-91.
29. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8.
30. Dlugosz L, Bracken MB. Reproductive effects of caffeine: a review and theoretical analysis. Epidemiol Rev 1992;14:83-100.